Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEGRO-100 ritlecitinib dose-comparison study in alopecia areata
jRCT2051250015Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (6 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants with absolute SALT score less than or equal to 20, Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuation and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2051250015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250015.